The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
For decades, countries such as India and China have flooded the U.S. market with low-cost generics, which are backed by heavy government subsidies and lax regulatory oversight. India’s Production Linked Incentives scheme alone has pumped billions of dollars into subsidizing India’s pharmaceutical exports. This uneven playing field has eroded the U.S. industrial base and left us dangerously dependent on opaque, overseas supply chains.
The consequences are not just economic; they’re personal and sometimes fatal.
Read the article.